The Hair Relaxer Ovarian Cancer MDL has grown into one of the largest product liability cases in the U.S. legal system, with over 14,700 total claims filed and 11,440 cases still pending as of March 2026. The litigation consolidates claims from individuals who developed ovarian, uterine, or endometrial cancer after using chemical hair relaxers manufactured by companies like L’Oréal, Revlon, Namaste Laboratories, Strength of Nature, Dabur, Godrej, Unilever, and Softsheen-Carson. This multidistrict litigation (MDL 3060) is the fourth-largest active MDL in the nation and represents a watershed moment for consumers seeking accountability from companies that sold these products without adequate cancer warnings.
The litigation is far from over—no settlements have been reached yet, but bellwether trials are expected to begin in 2027, with settlement checks potentially available within two years. The MDL was consolidated in the Northern District of Illinois under Judge Mary M. Rowland, who is overseeing the coordination of thousands of individual lawsuits into a single proceeding.
Table of Contents
- What Is the Hair Relaxer Ovarian Cancer MDL and How Did It Form?
- The Cancer Connection—What Does the Science Show?
- The Major Defendants and Their Financial Capacity
- Timeline for Settlements and Trial Schedule
- What Bellwether Cases Mean for the Broader Litigation
- Projected Settlement Amounts and Compensation Structure
- What Comes Next—Future Outlook for the Litigation
What Is the Hair Relaxer Ovarian Cancer MDL and How Did It Form?
The Hair Relaxer Ovarian Cancer MDL (MDL 3060) consolidated lawsuits filed by individuals who allege that long-term use of chemical hair relaxers caused them to develop reproductive cancers, primarily ovarian and endometrial cancer. Chemical hair relaxers have been a standard grooming product for decades, particularly in Black communities where they are widely used to straighten textured hair. The litigation emerged after scientific studies and epidemiological research suggested a correlation between frequent use of these products and elevated cancer risk, particularly among women who used them regularly over many years. The class of defendants named in the MDL is substantial and includes both major multinational corporations and smaller manufacturers. L’Oréal, one of the world’s largest cosmetics companies, faces significant exposure through its multiple hair care brands.
Revlon, a publicly traded cosmetics giant, has also been named and is currently navigating the litigation while in bankruptcy proceedings. Smaller manufacturers like Namaste Laboratories, Strength of Nature, Dabur, Godrej, and Unilever subsidiary Softsheen-Carson round out the defendant list. The consolidation of these claims into a single MDL allows for coordinated discovery, shared motion practice, and the eventual selection of bellwether cases to test liability and damages before a jury. The MDL structure allows the judicial system to manage the massive volume of similar claims efficiently rather than having thousands of individual trials clogging courthouses across the country. However, this also means that individual cases move at the pace set by the court’s trial schedule and settlement negotiations, not at the pace individual claimants might prefer.
The Cancer Connection—What Does the Science Show?
The underpinning of this litigation rests on epidemiological and toxicological evidence suggesting that certain chemicals found in hair relaxers—particularly phthalates, parabens, and other endocrine-disrupting compounds—may increase cancer risk when absorbed through the scalp over extended periods. A 2022 NIH study found that women who used hair relaxers four or more times per year had a 2.2-fold increased risk of ovarian cancer compared to those who never used them. The chemicals in these products penetrate the skin and scalp during application, and decades of repeated use may accumulate in body tissues, potentially triggering malignant changes in reproductive organs.
However, establishing a direct causation link in court is not straightforward. Defendants will argue that observed associations between hair relaxer use and cancer could be explained by other factors—lifestyle, genetics, environmental exposures, and the fact that cancer has multiple causes. The key challenge for plaintiffs is proving that the hair relaxer was a substantial factor in causing their cancer, not simply coincidental with it. This is precisely why bellwether trials are so important; they will allow juries in specific cases to weigh the evidence and establish precedent for what other juries might find reasonable regarding causation.
The Major Defendants and Their Financial Capacity
The defendant roster includes manufacturers with vastly different financial profiles. L’Oréal, owned by French luxury conglomerate LVMH, has substantial financial resources and no concerns about its ability to pay judgments or settlements. The company continues to defend the litigation vigorously, denying any causal link between its hair relaxer products and cancer. Revlon, the second-largest U.S.
Cosmetics manufacturer, presents a more complex scenario. The company filed for bankruptcy in 2022 (Chapter 11), yet it retains a substantial insurance policy specifically designed to cover product liability claims of this magnitude. While bankruptcy might seem to limit Revlon’s ability to pay settlements, the company’s insurance coverage and the structured nature of the MDL process mean that claimants are not left without recourse. Bankruptcy courts have set aside funds dedicated to resolving these types of claims. For smaller manufacturers like Namaste Laboratories and Strength of Nature, collective exposure is significant, though their individual financial capacity is more limited than L’Oréal or Revlon.
Timeline for Settlements and Trial Schedule
As of March 2026, no formal settlements have been announced, and all major defendants continue to defend the litigation on the merits. However, the MDL is rapidly approaching critical junctures that often trigger settlement discussions. Bellwether cases—a subset of claims selected to proceed to trial first—are expected to be chosen by early April 2026. These trials are typically scheduled to begin in 2027 and serve as a gauge for how juries evaluate liability and damages in this specific case. The timeline suggests that settlement negotiations will likely intensify once bellwether trial results become available.
If juries return verdicts in favor of plaintiffs in one or more bellwether cases, defendants face substantial financial exposure and may move toward global settlement discussions. Conversely, if defendants prevail in bellwether trials, settlement negotiations may stall or shift significantly. Based on typical MDL timelines, settlement checks could be distributed to claimants in 2027 or 2028, though this depends on how quickly settlements are negotiated and executed. One important caveat: MDL timelines often slip. While 2027 trials are projected, judicial delays, motions practice, and unforeseen complications could extend this schedule. Claimants should be prepared for the possibility that settlements may take longer than initially projected.
What Bellwether Cases Mean for the Broader Litigation
Bellwether cases are essentially test cases—the court selects a small number of claims (typically 4 to 10 in an MDL this size) that are representative of the broader plaintiff population and proceeds to trial with those cases first. The outcomes in bellwether trials provide crucial information about jury attitudes, the strength of causation evidence, and reasonable damage awards. Depending on the results, both sides use this information to guide settlement strategy. For plaintiffs, a successful bellwether verdict sends a strong signal to defendants that juries are willing to find liability and award substantial damages, which typically accelerates settlement negotiations.
For defendants, a favorable bellwether result may encourage them to continue litigating rather than settling. The selected cases are usually chosen to include a mix of strong and moderate claims, ensuring that the trials provide representative feedback to both sides. Claimants whose cases are selected as bellwethers will have their cases heard in federal court under Judge Mary M. Rowland’s supervision, with all the discovery and trial procedures that entails. Those whose cases are not selected will remain in the MDL pending queue, waiting for either a global settlement or their turn for individual trial—a wait that could extend years beyond the bellwether stage.
Projected Settlement Amounts and Compensation Structure
The potential settlement range for eligible claimants is wide but provides a useful benchmark for what participants might expect. For women diagnosed with ovarian, uterine, or endometrial cancer related to hair relaxer use, settlement projections range from $150,000 to $750,000 per plaintiff, depending on factors such as the severity of the cancer, age at diagnosis, prognosis, medical expenses, lost income, and quality-of-life impacts.
A plaintiff who developed ovarian cancer at age 45, required chemotherapy and surgery, and suffered lasting health complications and diminished earning capacity would likely fall toward the higher end of settlement compensation. By contrast, a plaintiff whose cancer was diagnosed earlier and treated successfully with fewer long-term effects might receive compensation in the lower to mid-range. These figures are projections based on comparable litigation and settlement patterns; actual amounts will depend on the specific facts of each case and the outcome of bellwether trials.
What Comes Next—Future Outlook for the Litigation
The period from April 2026 through 2027 will be pivotal for this litigation. Bellwether case selection and trial outcomes will reshape the landscape and determine whether the parties move toward settlement or continue the adversarial process. If settlements materialize, the next phase involves claims administration—a process where claimants submit documentation proving their eligibility (hair relaxer use history, cancer diagnosis, medical records) and receive compensation allocations based on the settlement agreement’s terms.
For those awaiting resolution, the message is clear: while compensation is likely to be available, the timeline extends into 2027 at the earliest. Claimants should ensure their case documentation is thorough and up-to-date, including medical records, purchase receipts for hair relaxer products, and any photographs or documentation of product use. Staying in regular contact with their attorneys ensures they receive timely updates as the litigation progresses through these critical phases.